Jay L. Koyner, MD, is an Associate Professor of Medicine in the Section of Nephrology at the University of Chicago. He completed his undergraduate degree in Biophysics at The Johns Hopkins University. He then went on to complete medical school at the State University of New York at Stony Brook where he awarded a degree with distinction in research following completion of a Howard Hughes Medical Institute Research Fellowship. Dr. Koyner completed his internal medicine and nephrology training at the University of Chicago, where he currently serves as the Medical Director of the Inpatient Dialysis Unit and Director of ICU Nephrology. He is an expert in the care of patients at risk for and diagnosed with acute kidney injury (AKI) . He is spoken nationally and internationally on AKI and a variety of topics in the field of Critical Care Nephrology. Over the last decade he has served many roles for the American Society of Nephrology, including being a member of the Acute Kidney Injury Advisory Group, Co-Director of the Critical Care Nephrology pre-course (2014 to 2018), Co-Editor of the Nephrology Self-Assessment Program (NephSAP) for Acute Kidney Injury and Critical Care Nephrology (2016 to 2019) and currently he sits on the Scientific Advisory Board of the National Kidney Foundation. He has served on the editorial review board of the Clinical Journal of the American Society of Nephrology, The American Journal of Nephrology and Advances in Chronic Kidney Disease. In addition to being a dedicated clinician educator, Dr. Koyner’s critical care nephrology research interests have focused on the utilization of plasma and urine biomarkers to improve patient risk stratification and outcomes in the setting of AKI. He has contributed to several multicenter studies investigating biomarkers of AKI, including the TRIBE-AKI study, the Furosemide Stress Test study and several industry sponsored investigations. More recently he has begun developing and implementing an electronic health record derived AKI risk score, with the goal of improving the care of patients at high risk for the development of severe hospital acquired AKI. He has published over 90 peer-reviewed articles and book chapters on AKI and the care of patients with kidney injury in the ICU.
The University of Chicago
Chicago. IL
- Nephrology
2006
The University of Chicago
Chicago
- Internal Medicine
2004
Stony Brook School of Medicine
Stony Brook, NY
MD - Medicine
2001
The Johns Hopkins University
Baltimore, MD
BA - Biophysics
1996
Serial Urinary C-C Motif Chemokine Ligand 14 and Risk of Persistent Severe Acute Kidney Injury.
Serial Urinary C-C Motif Chemokine Ligand 14 and Risk of Persistent Severe Acute Kidney Injury. Crit Care Explor. 2023 Mar; 5(3):e0870.
PMID: 36875557
Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup.
Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup. Nat Rev Nephrol. 2023 Feb 23.
PMID: 36823168
Outcomes, Healthcare Resource Utilization, and Costs of Overall, Community-Acquired, and Hospital-Acquired Acute Kidney Injury in COVID-19 Patients.
Outcomes, Healthcare Resource Utilization, and Costs of Overall, Community-Acquired, and Hospital-Acquired Acute Kidney Injury in COVID-19 Patients. J Health Econ Outcomes Res. 2023; 10(1):31-40.
PMID: 36852155
Care of the Hospitalized Patients with Kidney Failure during COVID-19 Pandemic: Lessons Learned.
Care of the Hospitalized Patients with Kidney Failure during COVID-19 Pandemic: Lessons Learned. Clin J Am Soc Nephrol. 2023 Jan 30.
PMID: 36795034
Cautious Optimism: Artificial Intelligence and Acute Kidney Injury.
Cautious Optimism: Artificial Intelligence and Acute Kidney Injury. Clin J Am Soc Nephrol. 2023 Jan 30.
PMID: 36795027
Pre-operative kidney biomarkers and risks for death, cardiovascular and chronic kidney disease events after cardiac surgery: the TRIBE-AKI study.
Pre-operative kidney biomarkers and risks for death, cardiovascular and chronic kidney disease events after cardiac surgery: the TRIBE-AKI study. J Cardiothorac Surg. 2022 Dec 25; 17(1):338.
PMID: 36567329
Risk Classification and Subphenotyping of Acute Kidney Injury: Concepts and Methodologies.
Risk Classification and Subphenotyping of Acute Kidney Injury: Concepts and Methodologies. Semin Nephrol. 2022 05; 42(3):151285.
PMID: 36470740
Clinical Outcomes of Persistent Severe Acute Kidney Injury among Patients with Kidney Disease Improving Global Outcomes Stage 2 or 3 Acute Kidney Injury.
Clinical Outcomes of Persistent Severe Acute Kidney Injury among Patients with Kidney Disease Improving Global Outcomes Stage 2 or 3 Acute Kidney Injury. Am J Nephrol. 2022; 53(11-12):816-825.
PMID: 36450235
Kidney health in the COVID-19 pandemic: An umbrella review of meta-analyses and systematic reviews.
Kidney health in the COVID-19 pandemic: An umbrella review of meta-analyses and systematic reviews. Front Public Health. 2022; 10:963667.
PMID: 36172213
Artificial Intelligence in Acute Kidney Injury Prediction.
Artificial Intelligence in Acute Kidney Injury Prediction. Adv Chronic Kidney Dis. 2022 09; 29(5):450-460.
PMID: 36253028
Mid-Career Award
American Society of Nephrology
2019